COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response Ali Farhoudian, Alexander Baldacchino, Nicolas Clark, Gilberto Gerra, Hamed Ekhtiari, Geert Dom, Azarakhsh Mokri, Mandana Sadeghi, Pardis Nematollahi, Maryanne Demasi, Christian G. Schütz, Seyed Mohammadreza Hashemian, Payam Tabarsi, Susanna Galea-singer, Giuseppe Carrà, Thomas Clausen, Christos Kouimtsidis, Serenella Tolomeo, Seyed Ramin Radfar, Emran Mohammad Razaghi An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper 29 mars 2020 Abstract : Coronavirus disease 2019 (COVID-19) is escalating across the world with higher morbidities and mortalities in certain vulnerable populations. People who use drugs (PWUD) are a marginalized and stigmatized group with [...]
Lire la suiteAddiction, précarité et confinement : Ne laissons pas de failles dans la protection commune… publié le 19/03/2020 | Imprimer Communiqué du 19 mars 2020 La mise en place du confinement pour ralentir la diffusion du COVID-19 a fortement mobilisée les équipes d’addictologie et de réduction des risques. Il s’agit d’éviter autant que possible de charger encore plus l’activité des urgences, des services hospitaliers et d’une médecine et pharmacie de ville déjà en surchauffe, en réduisant la transmission virale chez des personnes présentant toutes des troubles chroniques et qui seront donc autant de situations sévères en cas de contamination. Nos actions convergent [...]
Lire la suiteDetoxification from methadone using low, repeated, and increasing doses of ibogaine : A case report CLARE WILKINS, RAFAEL G. DOS SANTOS, JORDI SOLÁ, MARC AIXALÁ, PEP CURA, ESTEFANÍA MORENO, MIGUEL ÁNGEL ALCÁZAR-CÓRCOLES, JAIME E. C. HALLAK and JOSÉ CARLOS BOUSO Journal of Psychedelic Studies, 2017, 1, (1), pp. 29–34 DOI: 10.1556/2054.01.2017.005 Background and aims : Ibogaine is a natural alkaloid that has been used in the last decades as an adjuvant for the treatment of opiate withdrawal. Despite the beneficial results suggested by animal studies and case series, there is a lack of clinical trials to assess the safety and efficacy of ibogaine. Moreover, [...]
Lire la suite